XERIS PHARMACEUTICALS INC Selling, General and Administrative Expense
XERIS PHARMACEUTICALS INC reported Selling, General and Administrative Expense of $25.93 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2021-08-05
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2021-06-30 was $25.93M, a 46.95% increase year-over-year.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2021-03-31 was $19.08M, a 11.71% decline year-over-year.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2020-12-31 was $18.00M, a 12.81% decline year-over-year.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for the quarter ending 2020-09-30 was $16.48M, a 10.80% increase year-over-year.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2020 was $73.73M, a 16.92% increase from fiscal 2019.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2019 was $63.06M, a 198.68% increase from fiscal 2018.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2018 was $21.11M, a 163.42% increase from fiscal 2017.
- XERIS PHARMACEUTICALS INC selling, general and administrative expense for fiscal 2017 was $8.02M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2021-06-30 | $25.93M 10-Q · filed 2021-08-05 | $45.00M 10-Q · filed 2021-08-05 | $63.00M derived: sum of 3 quarters · filed 2021-08-05 | $79.49M derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | $19.08M 10-Q · filed 2021-05-13 | $37.08M derived: sum of 2 quarters · filed 2021-05-13 | $53.56M derived: sum of 3 quarters · filed 2021-05-13 | $71.20M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $34.48M derived: sum of 2 quarters · filed 2021-03-09 | $52.13M derived: sum of 3 quarters · filed 2021-08-05 | $73.73M 10-K · filed 2021-03-09 |
| 2020-09-30 | $16.48M 10-Q · filed 2020-11-09 | $34.13M derived: sum of 2 quarters · filed 2021-08-05 | $55.73M 10-Q · filed 2020-11-09 | $76.38M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | $17.64M 10-Q · filed 2021-08-05 | $39.25M 10-Q · filed 2021-08-05 | $59.89M derived: sum of 3 quarters · filed 2021-08-05 | $74.77M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $21.61M 10-Q · filed 2021-05-13 | $42.25M derived: sum of 2 quarters · filed 2021-05-13 | $57.13M derived: sum of 3 quarters · filed 2021-05-13 | $72.15M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $20.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $35.52M derived: sum of 2 quarters · filed 2021-03-09 | $50.54M derived: sum of 3 quarters · filed 2021-03-09 | $63.06M 10-K · filed 2021-03-09 |
| 2019-09-30 | $14.88M 10-Q · filed 2020-11-09 | $29.90M derived: sum of 2 quarters · filed 2020-11-09 | $42.42M 10-Q · filed 2020-11-09 | $51.14M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $15.02M 10-Q · filed 2020-08-10 | $27.54M 10-Q · filed 2020-08-10 | $36.27M derived: sum of 3 quarters · filed 2020-08-10 | $40.92M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $12.52M 10-Q · filed 2020-05-07 | $21.24M derived: sum of 2 quarters · filed 2020-05-07 | $25.89M derived: sum of 3 quarters · filed 2020-05-07 | $30.39M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $13.38M derived: sum of 2 quarters · filed 2020-03-12 | $17.87M derived: sum of 3 quarters · filed 2020-03-12 | $21.11M 10-K · filed 2020-03-12 |
| 2018-09-30 | $4.65M 10-Q · filed 2019-11-07 | $9.15M derived: sum of 2 quarters · filed 2019-11-07 | $12.39M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $4.50M 10-Q · filed 2019-08-06 | $7.74M 10-Q · filed 2019-08-06 | ||
| 2017-12-31 | $8.02M 10-K · filed 2019-03-06 |